Jick S S
Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, Massachusetts, USA.
Pharmacotherapy. 1999 Feb;19(2):221-2. doi: 10.1592/phco.19.3.221.30919.
We evaluated pregnancy outcomes in 234 women exposed to fluconazole, 492 exposed to a topically administered azole preparation, 88 exposed to an oral azole preparation other than fluconazole, and 1629 not exposed to any of these agents during the first trimester of pregnancy Relative risks of having a baby with a congenital disorder for women exposed to fluconazole, oral azoles, and topical azoles in the first trimester of pregnancy compared with those who were unexposed were 1.1 (95% CI 0.4-3.3), 2.1 (95% CI 0.7-6.8), and 0.6 (95% CI 0.2-1.6), respectively These results provide reassurance that fluconazole exposure in the first trimester of pregnancy does not materially increase the risk of congenital disorders in infants.
我们评估了234名在孕期头三个月接触氟康唑的女性、492名接触局部用唑类制剂的女性、88名接触除氟康唑外的口服唑类制剂的女性以及1629名在孕期头三个月未接触任何这些药物的女性的妊娠结局。与未接触者相比,孕期头三个月接触氟康唑、口服唑类和局部用唑类的女性生出先天性疾病患儿的相对风险分别为1.1(95%可信区间0.4 - 3.3)、2.1(95%可信区间0.7 - 6.8)和0.6(95%可信区间0.2 - 1.6)。这些结果让人放心,孕期头三个月接触氟康唑不会实质性增加婴儿患先天性疾病的风险。